STAT3 mediates Nilotinib response in KIT-altered Melanoma: a Phase II Multicenter Trial of the French Skin Cancer Network
| Description | |
| Auteurs | Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S and Lebbe C |
| Revue | J Invest Dermatol (), , 2017 |
| Année | 2 017 |
| Service | |
| Institut | |
| Laboratoire | |
| Date de création | 06/01/2017 |
| Facteur Impact | |